RT Journal Article
T1 Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19
A1 Rodilla, Enrique
A1 Saura, Alberto
A1 Jiménez, Iratxe
A1 Mendizábal, Andrea
A1 Pineda-Cantero, Araceli
A1 Lorenzo-Hernández, Elizabeth
A1 Fidalgo-Montero, Maria del Pilar
A1 Fernandez López-Cuervo, Joaquín
A1 Gil-Sánchez, Ricardo
A1 Rabadán-Pejenaute, Elisa
A1 Abella-Vázquez, Lucy
A1 Giner-Galvañ, Vicente
A1 Solís-Marquínez, Marta Nataya
A1 Boixeda, Ramon
A1 de la Peña-Fernández, Andrés
A1 Carrasco-Sánchez, Francisco Javier
A1 González-Moraleja, Julio
A1 Torres-Peña, José David
A1 Guisado-Espartero, María Esther
A1 Escobar-Sevilla, Joaquín
A1 Guzmán-García, Marcos
A1 Martín-Escalante, María Dolores
A1 Martínez-González, Ángel Luis
A1 Casas-Rojo, José Manuel
A1 Gómez-Huelgas, Ricardo
K1 Hypertension
K1 COVID-19
K1 Angiotensin-converting enzyme inhibitors (ACEIs)
K1 Angiotensin II receptor blockers (ARBs)
K1 All-cause mortality
AB It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.
PB MDPI
YR 2020
FD 2020-09-28
LK http://hdl.handle.net/10668/3366
UL http://hdl.handle.net/10668/3366
LA en
NO Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E, et al. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. J Clin Med. 2020 Sep 28;9(10):3136.
DS RISalud
RD Aug 6, 2025